BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 13, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Abiraterone acetate: Interim Phase III data

Johnson & Johnson unblinded the Phase III COU-AA-301 trial at the recommendation of an independent DMC after a pre-specified interim analysis showed that abiraterone plus prednisone met the primary endpoint of significantly improving OS vs. placebo plus prednisone and had an acceptable safety profile. Additionally, the committee recommended that patients in the placebo arm be offered treatment with...

Read the full 268 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >